

Please delete the paragraph and the section heading "Cross-Reference to Related Applications" at page 1, lines 10-15.

Please insert the following paragraph as the first paragraph after the title on page 1:

B1
--This application claims the benefit of U.S. Provisional Application No. 60/159,015, filed October 12, 1999; U.S. Provisional Application No. 60/159,210, filed October 13, 1999; U.S. Provisional Application No. 60/172,979, filed December 20, 1999; U.S. Provisional Application No. 60/173,388, filed December 28, 1999; and U.S. Provisional Application No. 60/186,626, filed March 3, 2000. The disclosure of each of the aforementioned applications is expressly incorporated herein by reference, in its entirety and for all purposes.--

IN THE ABSTRACT:

Please replace the title on page 65, line 2 with the following new title:

--METHODS OF TREATING A CCX CKR-MEDIATED DISEASE--

IN THE CLAIMS:

Appendix A entitled "Version with Markings to Show Changes Made" which is attached hereto shows the amendments that have been made to the claims. Appendix B entitled "Pending Claims" lists all the claims as pending following entry of this amendment.

Please cancel claims 1-32 without prejudice or disclaimer to reentry in this application or prosecution in another application. Please amend the following claims without prejudice or disclaimer:

B2
33. (Amended) A method of treating an CCX CKR-mediated condition in a mammal comprising administering to the mammal an agent that inhibits or promotes the binding of CCX CKR to ELC (EBI-1-ligand chemokine), SLC (secondary lymphoid organ chemokine), TECK (thymus expressed chemokine), BLC (B-lymphocyte chemoattractant), CTACK (cutaneous T